Efficacy of BCG Revaccination Compared With Oral Chemoprophylaxis in Household Contacts Aged 6-18 Years for Prevention of Tuberculosis Disease - A Phase III Open Labelled Randomised Controlled Trial

Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection. The efficacy of BCG vaccination in newborns is well known and has a documented protective effect against meningitis and disseminated TB in children. However, there is considerable uncertainty on BCG revaccination. It is known that BCG revaccination enhances immune responses, but it is yet to be established if BCG revaccination can help prevent TB disease in household contacts.
The primary aim of this study is to assess the efficacy of BCG revaccination compared to oral chemoprophylaxis in preventing TB disease in house hold contacts aged 6-18 years.
The study is designed as a multicentre randomised controlled trial with two groups of healthy household contacts aged 6-18 years receiving either the BCG vaccine or oral chemoprophylaxis. They will be followed up for 24 months to compare the incidence of TB disease in each arm.

开始日期2024-07-15

申办/合作机构

All India Institute of Medical Sciences

[+2]

NCT04938323

/ Withdrawn临床2/3期IIT

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE)

The purpose of this study is to assess the efficacy of Bacille Calmette-Guérin (BCG) vaccination compared to placebo against acute respiratory infections in the elderly who are less protected by standard vaccines against influenza than other age groups. The investigators hypothesize that BCG vaccination can reduce incidence of infection and severity of a range of acute respiratory infections. Patients who are residents of participating long-term care facilities (LTCFs), who agree to participate in the study, or with a legal guardian who agrees on their behalf, will be randomly assigned to receive BCG vaccination or a placebo. Participants will be followed for up to six months to assess the incidence of infection and the severity of a range of acute respiratory infections.

开始日期2022-05-01

申办/合作机构

Harvard Medical School

[+1]

NCT03928275

/ Withdrawn临床2/3期IIT

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

The investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional Interleukin-2 (IL-2) and Bacillus Calmette Guerin (BCG) to assess the utility of treating cutaneous metastatic melanoma (CMM).

开始日期2021-12-01

申办/合作机构

Nova Scotia Health Authority

[+1]

100 项与卡介苗(Organon) 相关的临床结果

登录后查看更多信息

100 项与卡介苗(Organon) 相关的转化医学

登录后查看更多信息

100 项与卡介苗(Organon) 相关的专利（医药）

登录后查看更多信息

229

项与卡介苗(Organon) 相关的文献（医药）

2024-12-01·Jornal de Pediatria

BCG vaccination in children with severe combined immunodeficiency in a tertiary center: evaluation of complications and risks

Article

作者: Maria E Silva, Jorgete ; Jamra, Soraya Regina Abu ; Roxo-Junior, Persio ; Botaro, Matheus Henrique ; Geraldino, Stephanie Zago

OBJECTIVETo describe the complications and risks associated with BCG (Bacillus Calmette-Guérin) vaccination in patients diagnosed with SCID (Severe Combined Immunodeficiency).METHODSThis is a descriptive case series study. Medical charts were retrospectively reviewed for demographics, clinical manifestation, laboratory findings at diagnosis, outcome, and diagnosis of BCG vaccine-associated complications.RESULTSEleven patients diagnosed with SCID were enrolled. Ten were male. Seven (64 %) were considered probable SCID, while four (36 %) were considered definite SCID (genetically confirmed). The median age at the onset of symptoms was one month; the median age at SCID diagnosis was four months. Respiratory symptoms were the most frequent. Eight patients were vaccinated within seven days of life. Seven (87 %) of these patients experienced BCG vaccine-associated complications (86 % disseminated reactions; 14 % localized reactions). BCG vaccine-associated complications were the first clinical manifestation in 75 % of the vaccinated patients. Less than half of the patients (36 %) underwent hematopoietic stem cell transplantation. The overall death rate was elevated (73 %); the death rate related to BCG vaccination was 25 %.CONCLUSIONSPatients with SCID can present a high rate of BCG vaccine-associated complications, which negatively impact the clinical outcome and mortality. Pediatricians must be aware that BCG vaccine-associated complications can be the first presentation and a warning sign of SCID. Implementing newborn screening for SCID in Brazil may represent a worthy opportunity to impact the health outcomes of affected infants significantly.

2024-12-01·Journal of Infection

The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases

Article

作者: Ten Oever, Jaap ; Moorlag, Simone J C F M ; Föhse, Konstantin ; Dulfer, Elisabeth A. ; Koekenbier, Eva L. ; Moorlag, Simone J.C.F.M. ; van Werkhoven, Cornelis H ; Netea, Mihai G ; Hoogerwerf, Jacobien J. ; Rosendaal, Frits R ; Bonten, Marc J M ; Rosendaal, Frits R. ; Taks, Esther J M ; Bonten, Marc J.M. ; ten Oever, Jaap ; Netea, Mihai G. ; Dulfer, Elisabeth A ; Hoogerwerf, Jacobien J ; Taks, Esther J.M. ; van de Maat, Josephine S. ; van de Maat, Josephine S ; Koekenbier, Eva L ; van Hylckama Vlieg, Astrid ; van Werkhoven, Cornelis H.

OBJECTIVESPrevious research has suggested beneficial heterologous effects of the Bacillus Calmette-Guérin (BCG) vaccine on non-mycobacterial infections and other immune-mediated diseases. During the COVID-19 pandemic, randomized controlled trials BCG-PRIME (n = 5349) and BCG-CORONA-ELDERLY (n = 1907) investigated the impact of BCG on SARS-CoV-2 infections in older individuals. We extended the follow-up in these studies by one year (BCG-Long Term study), to assess the overall effects of BCG vaccination on infectious and immune-mediated diseases in individuals aged over 60.METHODSPrior participants were invited to complete a one-year follow-up survey after their completion of the original trial. Data on vaccinations, hospital admissions, infectious episodes, and new medical diagnoses were collected and compared between BCG- and placebo-vaccinated participants. Variables of interest were combined with the previous trial databases and analyzed using relative risks (RR) and an adjusted Cox regression model accounting for participation probability.RESULTSThe response in the follow-up survey was 60%, including 4238 individuals in the final analysis (2317 had received BCG and 1921 placebo). Incidence and severity of infectious diseases and other diagnoses, including cardiovascular diseases and cancer, did not differ between the groups. The proportion of individuals hospitalized for cardiac arrhythmias after BCG was two-fold higher than reported after placebo (1.6% versus 0.8%, RR 2.0 (95% confidence interval 1.1-3.6)). Cardiac arrhythmia-related hospitalizations were primarily due to exacerbation of pre-existing arrhythmias.CONCLUSIONThe results of the present study confirm that BCG has no relevant effect on non-mycobacterial infectious diseases and other immune-mediated diseases in a population of generally mycobacteria-naïve older Dutch individuals in the two years following vaccination. However, our study suggests that BCG may aggravate pre-existing cardiac arrhythmia, which warrants further investigation.

2024-11-01·Nurse Education in Practice

Effect of standardized patient simulation with BCG vaccination on nursing students' skills, knowledge and satisfaction, and self-confidence: A randomized controlled study

Article

作者: Aydın, M. Okan ; Aydın, M Okan ; Alper, Züleyha ; Unal, Eda ; Ozdemir, Aysel

AIMTo examine the effect of standardised patient simulation training on nursing students' skills and knowledge in administering the Bacillus Calmette-Guérin vaccine, as well as their satisfaction and self-confidence.BACKGROUNDThe Bacillus Calmette-Guérin vaccine is administered by nurses to prevent tuberculosis. However, there have been reports of complications arising from inadequate knowledge and skills related to Bacillus Calmette-Guérin vaccine administration.DESIGNA randomised controlled experimental design.METHODThis experimental study was conducted between October 2022 and January 2023 at a university, Medical Training and Simulation Centre. The fourth-year nursing students enrolled in their intern term were asked to participate in this experimental study. Participants were allocated to the intervention group (n=45) and the control group (n=45). The control group received only theoretical training and then BCG application on the model. The socio-demographic survey was conducted to collect demographic data. The Bacillus Calmette-Guérin Vaccine Knowledge Form, Bacillus Calmette-Guérin Vaccine Administration Checklist, and the student satisfaction and self-confidence scale in learning were used. The intervention group received simulation training using a standardized patient. All students' knowledge and skills were measured before and 3 months after the theoretical training.RESULTSSimulation training using standardized patients significantly increased nursing students' Bacillus Calmette-Guérin vaccine knowledge (intervention group=21.57±5.12; control group=15.33±5.61), skills (intervention group=20.88±4.29; control group=10.22±4.56), confidence and satisfaction (intervention group=4.61±0.30; control group=4.17±0.3) compared with the control group (p < 0.05).CONCLUSIONTraining with standardized patient techniques provides students the opportunity to practice realistically in a safe environment, enabling repetitive practice, which enhances self-confidence and satisfaction.

项与卡介苗(Organon) 相关的新闻（医药）

2025-01-10

·Endpoints

Pfizer touts bladder cancer results as first advancement for some patients 'in decades'

Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where progress has been limited. Its therapy, called sasanlimab, significantly prolonged patients’ event-free survival in combination with the standard-of-care treatment Bacillus Calmette-Guérin, or BCG, compared to BCG alone, Pfizer announced on Friday. The Phase 3 trial enrolled patients with high-risk non-muscle invasive bladder cancer (NMIBC) who hadn’t received prior BCG treatment. Pfizer executives say that’s important in a disease where cancer recurs in roughly 40% to 50% of patients. While Merck’s blockbuster PD-1 Keytruda is approved to treat NMIBC patients who’ve already failed on BCG treatment, Pfizer has said its strategy is more ambitious. The company’s chief oncology officer Roger Dansey said in a news release on Friday that after seeing the data, he believes sasanlimab could be the first new option for BCG-naïve patients “in over 30 years.” All patients in the Phase 3 trial were given BCG as an initial treatment, followed by either sasanlimab alone, sasanlimab plus BCG maintenance therapy, or BCG maintenance therapy alone. The primary endpoint compared sasanlimab with BCG induction and maintenance therapy to BCG induction and maintenance therapy alone. Pfizer has yet to reveal the hard data, but said it will share more information at a future medical congress and with global regulators. A company spokesperson declined to comment on when an FDA submission might come. The company didn’t reveal much in terms of safety data, but said the results were “generally consistent with the known profile of BCG and data reported from clinical trials with sasanlimab.” It also said sasanlimab’s safety is “generally consistent” with that of other PD-1 inhibitors. Neal Shore, lead investigator on the Phase 3 trial, praised the results and said sasanlimab’s use could potentially “delay or reduce the need for more aggressive treatment options,” which sometimes include bladder removal surgery. A Pfizer spokesperson said an ongoing global shortage of BCG further emphasizes patients’ “high unmet need.”

临床3期临床结果

2024-12-20

·恒瑞医药

恒瑞医药创新药SHR-1501联合阿得贝利单抗用于膀胱癌获批临床

近日，恒瑞医药子公司上海恒瑞医药有限公司和上海盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准公司开展注射用SHR-1501（膀胱灌注）联合阿得贝利单抗注射液（静脉注射）用于非肌层浸润性膀胱癌的临床试验。尿路上皮癌（UC）主要包括肾盂、输尿管、膀胱的移行上皮恶性肿瘤，其中膀胱癌约占90%。2020年，全球范围内膀胱癌新发病例约57万例，死亡约21万例，在所有恶性肿瘤中分别排第12位和第14位1。根据国家癌症中心发布的国内癌症统计报告，2022年国内新发膀胱癌病例约9.3万例，死亡约4.1万例，在所有恶性肿瘤中排第11位2。非肌层浸润性膀胱癌（NMIBC）是指局限于膀胱黏膜层及固有层，且肌层未见浸润的膀胱恶性肿瘤，约75%膀胱癌的患者初诊时为NMIBC3。经尿道膀胱肿瘤切除术（TURBT）是NMIBC的标准治疗方式，也是重要诊断方法。NMIBC在TURBT术后复发率高4 ，因此推荐所有NMIBC患者进行术后辅助性膀胱灌注治疗，包括膀胱灌注化疗和膀胱灌注免疫治疗。对于高危NMIBC患者，推荐术后膀胱灌注卡介苗（BCG），预防复发及进展。依据2024 NCCN指南及2024 CSCO指南推荐，BCG经治失败的高危NMIBC标准治疗手段为根治性膀胱全切，膀胱全切后对患者生活影响很大，且带来沉重的经济负担。BCG经治失败的高危NMIBC目前缺乏有效的治疗手段保留膀胱，临床急需研发新的治疗药物，避免或延缓膀胱全切的时间。 SHR-1501是恒瑞医药自主研发并具有知识产权的白细胞介素-15（IL-15）融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥调动机体免疫系统清除体内异物（如肿瘤）的作用。与IL-2相比，IL-15不会刺激调节性T细胞增殖和诱导T细胞凋亡。目前国内未有相同靶点产品获批上市。阿得贝利单抗注射液是恒瑞医药自主研发的人源化抗PD-L1单克隆抗体，能通过特异性结合PD-L1分子从而阻断导致肿瘤免疫耐受的PD-1/PD-L1通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液（商品名：艾瑞利®）已于2023年3月获批上市，获批适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。该产品已被北京、上海、成都等多地纳入“惠民保”特药报销目录。公司现有多项阿得贝利单抗注射液临床研究正在进行，以评估其在非小细胞肺癌、小细胞肺癌、食管癌、肝癌等多种实体瘤中的抗肿瘤作用。参考文献： 1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 2.Han B, Zheng R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. 3.Ro JY, Staerkel GA, et al. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am. 1992 Aug;19(3):435-53. PMID: 1636229. 4.Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016;196:1021-9. 声明： 1.本新闻旨在分享研发前沿资讯，仅供医疗卫生专业人士参阅，非广告用途。 2.恒瑞医药不推荐任何未被批准的药品、适应症的使用。撰稿：王文亮高等会排版：程梦真责编：王玲往期精选 | 研发创新 | 慢病创新里程碑！恒瑞首个自免创新药夫那奇珠单抗获批上市恒瑞医药新突破！中国首个自研阿片类镇痛创新药富马酸泰吉利定获批上市 | 国际化 | 海外BD再传捷报！恒瑞医药GLP-1类创新药组合实现海外许可恒瑞医药与默克达成合作，携手推进癌症创新疗法 | 重磅奖项 | 喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！ | 社会公益 | “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

CSCO会议上市批准免疫疗法

2024-12-05

·FierceBiotech

Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial

Since yesterday, Protara Therapeutics\' stock has skyrocketed, jumping from $3.54 per share to about $6.75.\n At six months, Protara Therapeutics’ investigational cell therapy elicited a complete response (CR) rate of 72% among 18 patients with bladder cancer, data that sent the biotech’s shares surging.After nine months, two of out of three evaluable patients maintained their CRs, according to a Dec. 5 company release. In the phase 2 trial, no severe treatment-related adverse events had been reported by the data cutoff of Nov. 19.The open-label study, known as ADVANCED-2, enrolled patients with high-risk non-muscle invasive bladder cancer (NMIBC) who had not received or were unresponsive to Bacillus Calmette-Guérin (BCG), an immunotherapy used as the standard of care in the indication.The trial is testing Protara’s lead asset TARA-002, a cell therapy designed to activate immune cells within the tumor and generate a pro-inflammatory response. The data show that 13 of 18 patients (72%) across BCG exposures experienced CRs at six months, findings that are being shared today at the Society of Urologic Oncology’s annual meeting in Dallas. When zooming in on the patient population by BCG exposure, the pivotal cohort of BCG-unresponsive patients saw a 100% (4/4) CR rate at six months and an 80% (4/5) CR rate at any time. The cohort is designed to be registrational and aligns with FDA draft guidance for the specific patient population, according to Protara.In the proof-of-concept arm of BCG-naive patients, the CR rate was 64% (9/14) at six months and 67% (10/15) at any time.No patients discontinued due to adverse events, and there weren’t any treatment-related adverse events at or above a grade 2 level, the company said. In general, most adverse events were grade 1 and transient, according to the New York-based biotech, with the most common symptoms in line with typical responses to bacterial immunopotentiation. “These impressive TARA-002 results demonstrate meaningful activity in a difficult to treat patient population,” Brian Mazzarella, M.D., study investigator and vice president of research for Urology America, said in the release. “The activity of TARA-002 across BCG exposures, coupled with its ease of use and low procedural burden for physicians, make it an exciting potential treatment option for NMIBC patients.” The biotech is expected to report 12-month data from the trial in mid-2025, according to Protara CEO Jesse Shefferman.Since yesterday, Protara’s stock has skyrocketed, jumping from $3.54 per share at market close to $6.76 at 2:13 p.m. ET today.NMIBC makes up about 80% of bladder cancer cases, with around 65,000 Americans diagnosed with the form of bladder cancer every year.Earlier this year, ImmunityBio landed an FDA approval for its immunotherapy Anktiva in conjunction with BCG for BCG-unresponsive patients.Pharma data intelligence outlet Evaluate recently listed the interleukin-15 superagonist as one of the top 10 drug launches expected this year, forecasting that the immunotherapy could reach nearly $900 million in 2028 sales. The standard-of-care BCG is a vaccine supplied to the U.S. by Merck & Co. The med is used as to protect against tuberculosis and to stop or slow bladder cancer\'s growth.

免疫疗法临床2期上市批准疫苗临床结果

100 项与卡介苗(Organon) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AX03	DB12768

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱原位癌	美国	Merck & Co., Inc.	1989-06-21
乳头状癌	美国	Merck & Co., Inc.	1989-06-21
结核	美国	Merck & Co., Inc.	1989-06-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	临床3期	英国	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	美国	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	奥地利	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	日本	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	德国	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	比利时	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	芬兰	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	法国	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	中国	Merck Sharp & Dohme Corp.	2018-12-24
非肌层浸润性膀胱肿瘤	临床3期	瑞士	Merck Sharp & Dohme Corp.	2018-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02808143 (Pubmed) 人工标引	临床1期	膀胱癌	9	BCG vaccine+Pembrolizumab	(憲窪膚鏇衊蓋壓製簾淵) = 鏇製淵憲鏇構憲醖繭憲繭蓋憲壓製鑰鹹蓋襯餘 (範鬱繭膚衊製醖鬱餘簾 ) 更多	积极	2022-08-22
NCT04414267 (ACTIVATEII \| ACTIVATE-2, Pubmed) 人工标引	临床4期	新型冠状病毒感染	301	BCG vaccine	蓋淵鏇獵憲鏇壓遞膚膚(鬱鏇壓鬱廠淵衊壓壓鏇): OR = 0.32 (95% CI, 0.13 ~ 0.79) 更多	积极	2022-07-05
				Placebo
NCT02792192 (GU-123, CTgov)	临床1/2期	非肌层浸润性膀胱肿瘤	24	Atezolizumab (Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC))	衊窪襯鹹鑰醖鏇網夢夢(築淵窪願願壓窪夢鏇網) = 鹽繭鹽餘簾鬱淵繭鹽選顧膚範構壓糧膚艱築壓 (糧衊觸遞鏇夢膚廠膚鏇, 構鏇鹽餘網餘鏇鹹廠膚 ~ 醖製遞醖顧醖製範艱醖) 更多	-	2021-10-28
				Bacille Calmette-Guérin+Atezolizumab (Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC))	衊窪襯鹹鑰醖鏇網夢夢(築淵窪願願壓窪夢鏇網) = 艱淵選壓窪願廠淵選觸顧膚範構壓糧膚艱築壓 (糧衊觸遞鏇夢膚廠膚鏇, 網齋觸鹽窪窪繭構廠觸 ~ 簾製構顧憲積獵憲範蓋) 更多
AUA2021	N/A	非肌层浸润性膀胱肿瘤维持	422	BCG Connaught	糧獵網顧夢餘壓鏇觸艱(製顧築遞鏇積餘衊艱壓): HRRFS = 0.63 (95% CI, 0.46 ~ 0.86); HRTICE = 0.58 (95% CI, 0.39 ~ 0.86)	-	2021-09-01
				BCG TICE
NCT00070070 (CTgov)	临床1期	膀胱尿路上皮癌 \| 尿路上皮癌	6	TICE®-strain BCG+NY-ESO-1 protein+sargramostim (Cohort 1)	積鬱糧獵艱簾鏇願衊選(範顧壓製餘鹹餘廠繭窪) = 鑰夢範廠餘觸夢網膚觸願遞獵製衊襯積鏇築衊 (鏇糧膚衊夢廠網積鬱廠, 蓋鏇遞蓋繭鹽蓋齋壓鹹 ~ 製顧衊齋醖廠築選製窪) 更多	-	2021-07-08
				TICE®-strain BCG+NY-ESO-1 protein+sargramostim (Cohort 2)	積鬱糧獵艱簾鏇願衊選(範顧壓製餘鹹餘廠繭窪) = 醖鹹鹽選選製襯膚糧願願遞獵製衊襯積鏇築衊 (鏇糧膚衊夢廠網積鬱廠, 築網壓餘顧遞糧憲顧膚 ~ 廠餘壓構鬱繭顧鏇膚願) 更多
ASCO2020	N/A	非肌层浸润性膀胱肿瘤	412	BCG (High-grade Ta (TaHG), T1, and/or carcinoma-in-situ (CIS))	獵鏇構廠淵製壓構廠衊(憲觸壓鏇積觸簾鹽鹹襯) = 衊夢積鹽襯獵築齋構網獵積願蓋鏇艱衊繭襯餘 (蓋壓衊艱築築鹽襯艱艱 ) 更多	-	2020-05-25
AACR2012	临床3期	非肌层浸润性膀胱肿瘤	149	BCG Tice	(廠獵淵遞廠衊範顧廠壓) = 鑰膚觸糧構壓蓋艱獵鏇齋餘襯鏇鏇範憲構鑰鑰 (網蓋願憲顧製衊齋鹹壓 )	-	2012-04-15
				BCG Connaught	(廠獵淵遞廠衊範顧廠壓) = 鏇願積簾觸鑰蓋獵襯襯齋餘襯鏇鏇範憲構鑰鑰 (網蓋願憲顧製衊齋鹹壓 )
1672 (AUA2012)	临床3期	-	149	Onco-Tice	(製窪鏇夢積蓋鬱鑰艱鏇) = 築襯壓餘齋積繭淵築夢鏇鬱簾蓋簾網製窪廠廠 (襯夢壓顧選顧衊範選選 ) 更多	-	2012-04-01
				ImmuCyst (BCG Connaught)	(製窪鏇夢積蓋鬱鑰艱鏇) = 膚顧襯製願壓夢窪積醖鏇鬱簾蓋簾網製窪廠廠 (襯夢壓顧選顧衊範選選 ) 更多